Rollins-Raval and coworkers have confirmed these findings and have reported CD123 overexpression (by immunohistochemistry) in 83% of FLT3-ITD-mutaed AMLs and in 62% of AML cases with mutated NPM1 [56]. This evidence concerns the gene NPM1 and acute myeloid leukemia.